Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 28, 2026

AstraZeneca COPD Breakthrough Puts Tozorakimab And Valuation In Sharper Focus

View original at finance.yahoo.com

AstraZeneca COPD Breakthrough Puts Tozorakimab And Valuation In Sharper Focus Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

The price sits roughly 14% below consensus analyst target
60% confidence
Simply Wall St flags a high level of debt as a risk for AstraZeneca
60% confidence
AstraZeneca shares are trading about 41.1% below an estimated fair value
60% confidence

Data points we hold from this source

AstraZeneca AB · analyst price target	165.33 GBP
AstraZeneca AB · pe ratio	28.8 ratio